ScubaTx is making significant strides in organ transplant technology and has opened a new Manchester office to pave the way for future growth.
- The Newcastle-based company, founded by Dr. William Scott, received £1.4 million in funding, building on a previous successful round.
- ScubaTx employs a process called ‘persufflation’ to extend the viability of donated organs through controlled cooling and oxygenation.
- With the establishment of its Manchester base, ScubaTx aims to engage with commercial partners, particularly in the US, leveraging Manchester’s rich life sciences resources.
- The recent funding round led by GMC Life Sciences Fund will help accelerate ScubaTx’s goal of revolutionizing the organ transplantation process.
ScubaTx is at the forefront of revolutionizing organ transplant technology, having just opened a new office in Manchester Science Park. The expansion follows a successful £1.4 million funding round aimed at furthering the development of its groundbreaking organ preservation device. The company remains committed to advancing transplantation methodologies to help increase the number of donated organs reaching recipients.
Originating as a spinout from Newcastle University, ScubaTx was established by Chief Scientific Officer Dr. William (Bill) Scott and is currently led by CEO David Campbell. The organization leverages an advanced process known as ‘persufflation’, which enables the cooling and oxygenation of donated organs with humidified gas at controlled pressures and flow rates. This method significantly extends the viability of organs, thus enhancing transplant success rates.
The new office in Manchester hosts a team of twelve, including six recent hires, focusing on expanding capabilities across various sectors such as operational, quality assurance, regulatory affairs, mechanical, electrical, and software engineering. This strategic location allows ScubaTx to tap into the abundant life sciences expertise available in Manchester and the broader North West region.
As ScubaTx enhances its footprint in Manchester, the move is seen as a pivotal moment for the company. This step marks the transition from a virtual entity to a tangible presence, thus allowing ScubaTx to enhance collaboration with future commercial partners, including those in the United States where interest continues to grow.
The latest funding round was led by the GMC Life Sciences Fund By Praetura, a collaborative fund that also comprises Bruntwood SciTech, Enterprise Cheshire and Warrington, and Greater Manchester Combined Authority. This financial backing, alongside additional investors and Innovate UK grants, reinforces ScubaTx’s mission to innovate in organ transplantation, potentially saving countless lives and improving patient outcomes worldwide.
ScubaTx’s expansion into Manchester heralds a new era in organ transplantation technology, bolstered by significant financial support and strategic partnerships.
